logo BDSP

Base documentaire


Votre avis nous intéresse

Le réseau BDSP met en oeuvre un projet d'innovation et d'amélioration de ses services, dans le souci constant de proposer des contenus de qualité adaptés aux besoins des utilisateurs.

Identifier de nouvelles sources de financements est la condition nécessaire pour assurer la poursuite et la pérennité de cet outil unique qu'est la BDSP, tout en le faisant évoluer.

Pour définir un nouveau modèle économique, nous avons besoin de votre avis : merci de répondre à notre enquête (temps estimé : 5 minutes).

Participer maintenant
Participer plus tard J'ai déjà participé

  1. Long-term survival and development of secondary malignancies in patients with acute myeloid leukemia treated with aclarubicin or daunorubicin plus cytosine arabinoside followed by intensive consolidation chemotherapy in a Danish national phase III trial.

    Article - En anglais

    In 1991 we reported the results from a prospective randomised phase 3 trial comparing 7 days continuous infusion of cytosine arabinoside (ara-C) combined with either daunorubicin (DNR) or aclarubicin (ACR) as direct i.v. injection for 3 days as induction chemotherapy (CT) for patients with de novo acute myeloid leukemia (AML) followed by early intensive consolidation CT with two alternating cycles of high-dose ara-C and two cycles of amsacrine plus etoposide, and finally 3 days of daunomycin plus 7 days of ara-C as administered for induction of remission.

    A total of 174 patients with de novo AML in the age group 17-65 years were included.

    The patients have now been followed till death or for at least 7 years, and an evaluation of the long-term survival and the risk of developing secondary neoplasms has been made.

    The overall survival rate 5-years after diagnosis was 23%, and after 10 years 19%. No difference was found between the two treatment regimens in overall survival or disease-free survival (DFS).

    For the subgroup of 99 patients who achieved complete remission after one or two induction courses, 5-and 10-year survival rates were 35% and 31% respectively, with the highest survival rates in the age group 17-39 years (57% at 5 years) as compared with 27% in patients aged 40-60 years (P=0.007).

    Seven secondary neoplasms were diagnosed simultaneously with or after the diagnosis of AML indicating a standardized incidence ratio (SIR) of 3.41, (95% Cl : 1.60-7.26). (...)

    Mots-clés Pascal : Leucémie myéloblastique, Essai clinique phase III, Chimiothérapie, Aclarubicine, Antibiotique, Anticancéreux, Daunorubicine, Association médicamenteuse, Etude longitudinale, Cytarabine, Agent intercalant, Inhibiteur enzyme, Amsacrine, DNA topoisomerase (ATP-hydrolysing), Isomerases, Enzyme, Etoposide, Antimitotique, Survie, Long terme, Aigu, Pronostic, Second cancer, Complication, Traitement, Epidémiologie, Homme, Hémopathie maligne, Anthracyclines, Pyrimidine nucléoside, Acridine dérivé

    Mots-clés Pascal anglais : Acute myelocytic leukemia, Phase III trial, Chemotherapy, Aclarubicin, Antibiotic, Antineoplastic agent, Daunorubicin, Drug combination, Follow up study, Cytarabine, Intercalating agent, Enzyme inhibitor, Amsacrine, DNA topoisomerase (ATP-hydrolysing), Isomerases, Enzyme, Etoposide, Antimitotic, Survival, Long term, Acute, Prognosis, Second cancer, Complication, Treatment, Epidemiology, Human, Malignant hemopathy, Anthracyclins, Pyrimidine nucleoside, Acridine derivatives

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 97-0160758

    Code Inist : 002B02R02. Création : 21/05/1997.